Early Use of Novel Biologics in Psoriatic Arthritis: An Evolving Standard of Care

Hear expert insights on when to use interleukin inhibitors in the course of psoriatic arthritis. Review key data on using these novel agents for DMARD-refractory disease with an on-demand expert presentation and focused commentary.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Novartis Pharmaceuticals Corporation